Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Review H2 2017 provides an overview of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape. Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease Dugs (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Purchase This Non Alcoholic Fatty Liver Disease Pipeline Review H1 2017 Report of 202 Pages with Company profiles and Drugs Analysis at http://www.reportsnreports.com/purchase.aspx?name=1125833 .
The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 15, 11, 22, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively. Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Get Discount on This Report at: http://www.reportsnreports.com/contacts/discount.aspx?name=1125833 .
The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Non Alcoholic Fatty Liver Disease (NAFLD) -Companies Involved in Therapeutics Development Analyzed: Akcea Therapeutics Inc , Allergan Plc , Ardelyx Inc , AstraZeneca Plc , Betagenon AB , Bird Rock Bio Inc , Boehringer Ingelheim GmbH , Can-Fite BioPharma Ltd , Cerenis Therapeutics Holding SA , CJ HealthCare Corp , Conatus Pharmaceuticals Inc , Corcept Therapeutics Inc , CymaBay Therapeutics Inc , Daewoong Pharmaceutical Co Ltd , Dimerix Bioscience Pty Ltd , Dr. Falk Pharma GmbH , DURECT Corp , Enanta Pharmaceuticals Inc , Eternygen GmbH , Galmed Pharmaceuticals Ltd , Gemphire Therapeutics Inc , Genfit SA , Gilead Sciences Inc , Huons Co Ltd , Immuron Ltd , Kyorin Pharmaceutical Co Ltd , Matinas BioPharma Holdings Inc , Metacrine Inc , Miyarisan Pharmaceutical Company Ltd , Nordic Bioscience A/S , NovaTarg Therapeutics Inc , Ocera Therapeutics Inc , Pfizer Inc , Renova Therapeutics Inc , Sancilio & Company Inc , Shenzhen HighTide Biopharmaceutical Ltd , TaiwanJ Pharmaceuticals Co Ltd , TCM Biotech International Corp , Zydus Cadila Healthcare Ltd
Non Alcoholic Fatty Liver Disease (NAFLD) Drugs Profile Mentioned In Report: (leucine + metformin hydrochloride + sildenafil citrate), (leucine + PDE5 Inhibitor) , AC-261066 , AF-102 , AKCEA-ANGPTL3LRx , Aramchol , ARI-3037MO , AZD-4076 , C-10 , CBM-588, cenicriviroc mesylate , CER-209 , CJ-14199 , CORT-118335 , dabigatran etexilate mesylate , DMX-300 86, Drug to Antagonize MCJ for Gastrointestinal Disorders , DUR-928, DWP-10292 , EDP-305 , elafibranor, emricasan , FGF-1 Program, FLB-12 114, gemcabene calcium , GS-9674 , HTD-1801 , HU-002 , IMM-124E , KBP-089 , KM-2702 , liothyronine sodium , MAT-8800 , MN-002, naltrexone hydrochloride , Namacizumab , namodenoson , ND-630 , NLM-0100 , norursodeoxycholic acid , O-304 , oltipraz , ornithine phenylacetate , PF-06835919 , RDX-023 , RT-200 , RT-210 , saroglitazar , SC-410 , seladelpar lysine
The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources and covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
Report features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Non Alcoholic Fatty Liver Disease (NAFLD) – Overview
Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Development
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Non Alcoholic Fatty Liver Disease (NAFLD) – Companies Involved in Therapeutics Development
Non Alcoholic Fatty Liver Disease (NAFLD) – Dormant Projects
Non Alcoholic Fatty Liver Disease (NAFLD) – Discontinued Products
Non Alcoholic Fatty Liver Disease (NAFLD) – Product Development Milestones
Featured News & Press Releases
Expert Panel Validation
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441